Saturday Feb 11 | Diabetes Mine
Ask D'Mine: Lantus and Bleeding, Lantus in Winter
Diabetes isn't very loving, but here at the 'Mine , we're here to support you! Welcome to another edition of our weekly advice column, Ask D'Mine , hosted by veteran type 1, diabetes author and community educator Wil Dubois.
Sanofi: 2011 Results Benefit from Genzyme Acquisition
Change at Change at Q4 2011 Change on a constant 2011 Change on a constant ------- ----------- --------- ---- ----------- --------- reported reported basis exchange rates basis exchange rates --------- -------------- --------- -------------- euro euro Net sales 8,508m +8.8% +9.2% 33,389m +3.2% +5.3% Business net euro income 2,077m +13.0% +11.7% ... (more)
UPDATE 1-Sanofi confirms 2012 earnings dip
Sanofi said it was set to return to growth after 2012 -- a year in which sales will be hit by generic competition, as the French drugmaker met forecasts with a 13 percent rise in fourth-quarter profit.
Drugmaker Sanofi reports quarterly earnings up, warns of patent loss impact on 2012 profit
Drugmaker Sanofi SA says its earnings rose in the fourth quarter thanks to its acquisition of U.S. biotechnology firm Genzyme as well as double-digit growth in its consumer healthcare, diabetes and emerging markets businesses.
Newer insulins key for type two diabetes
It's not often you can take a true story based on a young man who gets cancer before slowly... Historically, patients go through three phases for control.
Long-term effects of insulin glargine on the risk of breast cancer.
There have been growing concerns regarding the long-term effects of insulin glargine on the risk of breast cancer.
Addition of insulin glargine or NPH insulin to metformin monotherapy...
Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly.
Also on Topix